Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2007 2
2008 4
2009 3
2010 5
2011 2
2012 3
2013 4
2014 5
2015 6
2016 3
2017 2
2018 3
2019 3
2020 12
2021 14
2022 12
2023 12
2024 13
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: abe m. Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838011 Clinical Trial.
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K. Iihara H, et al. Among authors: abe m. Int J Clin Oncol. 2024 Jul;29(7):873-888. doi: 10.1007/s10147-024-02535-x. Epub 2024 May 16. Int J Clin Oncol. 2024. PMID: 38753042 Free PMC article.
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
Kobayashi M, Kako J, Iba A, Okuyama A, Ozawa K, Abe M, Wada M, Akechi T, Iihara H, Imamura CK, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iino K. Kobayashi M, et al. Among authors: abe m. Int J Clin Oncol. 2024 Jul;29(7):889-898. doi: 10.1007/s10147-024-02536-w. Epub 2024 May 9. Int J Clin Oncol. 2024. PMID: 38722486
Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study).
Akechi T, Furukawa TA, Noma H, Iwata H, Toyama T, Higaki K, Matsuoka H, Zenda S, Iwatani T, Akahane K, Inoue A, Sagara Y, Uchida M, Imai F, Momino K, Imaizumi G, Yamaguchi T, Mashiko T, Miyaji T, Horikoshi M, Sakurai N, Onishi T, Kanemitsu Y, Murata T, Wanifuchi-Endo Y, Kuroda H, Nishikawa R, Miyashita M, Abe M, Uchitomi Y; J‐SUPPORT 2001 Study group. Akechi T, et al. Among authors: abe m. Psychiatry Clin Neurosci. 2024 Jun;78(6):353-361. doi: 10.1111/pcn.13657. Epub 2024 Mar 11. Psychiatry Clin Neurosci. 2024. PMID: 38468404 Free PMC article. Clinical Trial.
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M, Yamaguchi T, Fujita Y, Nishimura T, Kitagawa K, Inui N, Hirano K, Sakata Y, Iihara H, Shibuya Y, Suzuki K, Shibata K, Hori K, Daga H, Nakayama T, Sakata Y, Takahashi TY, Zenda S, Hashimoto H. Abe M, et al. JAMA Netw Open. 2023 May 1;6(5):e2310894. doi: 10.1001/jamanetworkopen.2023.10894. JAMA Netw Open. 2023. PMID: 37129897 Free PMC article. Clinical Trial.
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Murakami M, et al. Among authors: abe m. Int J Clin Oncol. 2025 Jan;30(1):27-39. doi: 10.1007/s10147-024-02663-4. Epub 2024 Nov 21. Int J Clin Oncol. 2025. PMID: 39570460
Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Tamura D, Abe M, Hiraki H, Sasaki N, Yashima-Abo A, Ikarashi D, Kato R, Kato Y, Maekawa S, Kanehira M, Takata R, Maejima K, Sasagawa S, Fujita M, Suzuki Y, Nakagawa H, Iwaya T, Nishizuka SS, Obara W. Tamura D, et al. Among authors: abe m. Cancer Sci. 2024 Feb;115(2):529-539. doi: 10.1111/cas.16025. Epub 2023 Dec 11. Cancer Sci. 2024. PMID: 38083992 Free PMC article.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Yokomizo A, Nakashima K, Iba A, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Yokomizo A, et al. Among authors: abe m. Int J Clin Oncol. 2024 Nov;29(11):1632-1640. doi: 10.1007/s10147-024-02624-x. Epub 2024 Sep 28. Int J Clin Oncol. 2024. PMID: 39340704
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H. Hayashi T, et al. Among authors: abe m. Int J Clin Oncol. 2024 Nov;29(11):1616-1631. doi: 10.1007/s10147-024-02623-y. Epub 2024 Sep 11. Int J Clin Oncol. 2024. PMID: 39259324
96 results